[Pubmed] Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in J
Posté : 12 nov. 2023 12:00
J Neuroimmunol. 2023 Nov 7;385:578241. doi: 10.1016/j.jneuroim.2023.578241. Online ahead of print.
ABSTRACT
This study included 51 patients with muscle-specific kinase antibody-positive myasthenia gravis (MuSK-MG) from a Japanese multicenter survey to examine clinical features and outcomes. Median onset age was 37 years and female predominance was observed. All patients developed generalized symptoms and almost all (50/51) patients had bulbar symptoms. About half of the patients met the criteria for refractory MG. The refractory group had a lower age of onset, higher severity scores, and higher maximum daily doses of oral prednisolone compared to the nonrefractory group. The outcomes for MuSK-MG patients in Japan are not favorable, indicating the need for more aggressive treatment.
PMID:37952282 | DOI:10.1016/j.jneuroim.2023.578241
Source: https://pubmed.ncbi.nlm.nih.gov/3795228 ... t6+86293ac